Lymphocyte therapy of renal cell carcinoma (Q36334899)

13 August 2017

1 reference

title

Lymphocyte therapy of renal cell carcinoma (English)

1 reference

13 August 2017

0 references

Robert O Dillman

1

1 reference

13 August 2017

publication date

1 December 2005

1 reference

Expert Review of Anticancer Therapy

13 August 2017

published in

1 reference

13 August 2017

volume

5

1 reference

13 August 2017

issue

6

1 reference

13 August 2017

page(s)

1041-1051

1 reference

13 August 2017

cites work

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1586/14737140.5.6.1041

Renal cell carcinoma: a priority malignancy for development and study of novel therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.5.6.1041

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.5.6.1041

Kinase inhibition with BAY 43-9006 in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.5.6.1041

Spontaneous regression of metastatic renal cancer. Case report and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.5.6.1041

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.5.6.1041

Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.5.6.1041

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.5.6.1041

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.5.6.1041

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.5.6.1041

A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.5.6.1041

Lymphokine-activated killer cells: biology and relevance to disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.5.6.1041

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.5.6.1041

Inpatient continuous-infusion interleukin-2 in 788 patients with cancer. The National Biotherapy Study Group experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.5.6.1041

Continuous infusion of recombinant interleukin-2 with or without autologous lymphokine activated killer cells for the treatment of advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.5.6.1041

Randomized Study of Interleukin 2 (IL-2) Alone vs IL-2 Plus Lymphokine-Activated Killer Cells for Treatment of Melanoma and Renal Cell Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.5.6.1041

New directions in natural killer cell-based immunotherapy of human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.5.6.1041

Effect of autolymphocyte therapy on survival and quality of life in patients with metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.5.6.1041

Treatment of human solid malignancies with autologous activated lymphocytes and cimetidine: a phase II trial of the cancer biotherapy research group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.5.6.1041

Growth of tumor-derived activated T cells for the treatment of advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.5.6.1041

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.5.6.1041

Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.5.6.1041

Antileukemic Effect of Graft-versus-Host Disease in Human Recipients of Allogeneic-Marrow Grafts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.5.6.1041

Allogeneic stem-cell transplantation for renal-cell cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.5.6.1041

CD8 cytotoxic T lymphocytes isolated from allogeneic healthy donors recognize HLA class Ia/Ib-associated renal carcinoma antigens with ubiquitous or restricted tissue expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.5.6.1041

Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.5.6.1041

Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.5.6.1041

Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.5.6.1041

Nonmyeloablative stem cell transplantation in metastatic renal cell carcinoma: delayed graft-versus-tumor effect is associated with chimerism conversion but transplantation has high toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.5.6.1041

Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.5.6.1041

Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago Experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.5.6.1041

Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.5.6.1041

Allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen for treatment of metastatic renal cell carcinoma: single institution experience with a minimum 1-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.5.6.1041

Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.5.6.1041

Regulation of somatic-cell therapy and gene therapy by the food and drug administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.5.6.1041

10.1586/14737140.5.6.1041

21 January 2018

Identifiers

DOI

1 reference

release_tu3bo6vuvjaxfc5eetenlydsi4

13 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/tu3bo6vuvjaxfc5eetenlydsi4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference